Tea Drinkers Live Longer

Four Green Teas in White Bowls Credit: A Girl With Tea / Wikimedia Commons
Drinking tea at least three times a week is linked with a longer and healthier life, according to a study published today in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology (ESC). "Habitual tea consumption is associated with lower risks of cardiovascular disease and all-cause death," said first author Dr. Xinyan Wang, Chinese Academy of Medical Sciences, Beijing, China. "The favorable health effects are the most robust for green tea and for long-term habitual tea drinkers." The analysis included 100,902 participants of the China-PAR project with no history of heart attack, stroke, or cancer. Participants were classified into two groups: habitual tea drinkers (three or more times a week) and never or non-habitual tea drinkers (less than three times a week) and followed-up for a median of 7.3 years. Habitual tea consumption was associated with more healthy years of life and longer life expectancy. For example, the analyses estimated that 50-year-old habitual tea drinkers would develop coronary heart disease and stroke 1.41 years later and live 1.26 years longer than those who never or seldom drank tea. Compared with never or non-habitual tea drinkers, habitual tea consumers had a 20% lower risk of incident heart disease and stroke, 22% lower risk of fatal heart disease and stroke, and 15% decreased risk of all-cause death. 

Green tea, Credit: MASA / Wikimedia Commons

The potential influence of changes in tea drinking behavior were analysed in a subset of 14,081 participants with assessments at two time points. The average duration between the two surveys was 8.2 years, and the median follow-up after the second survey was 5.3 years. Habitual tea drinkers who maintained their habit in both surveys had a 39% lower risk of incident heart disease and stroke, 56% lower risk of fatal heart disease and stroke, and 29% decreased risk of all-cause death compared to consistent never or non-habitual tea drinkers. Senior author Dr. Dongfeng Gu, Chinese Academy of Medical Sciences, said: "The protective effects of tea were most pronounced among the consistent habitual tea drinking group. Mechanism studies have suggested that the main bioactive compounds in tea, namely polyphenols, are not stored in the body long-term. Thus, frequent tea intake over an extended period may be necessary for the cardioprotective effect." In a subanalysis by type of tea, drinking green tea was linked with approximately 25% lower risks for incident heart disease and stroke, fatal heart disease and stroke, and all-cause death. However, no significant associations were observed for black tea. Dr. Gu noted that a preference for green tea is unique to East Asia. "In our study population, 49% of habitual tea drinkers consumed green tea most frequently, while only 8% preferred black tea. The small proportion of habitual black tea drinkers might make it more difficult to observe robust associations, but our findings hint at a differential effect between tea types." Two factors may be at play. First, green tea is a rich source of polyphenols which protect against cardiovascular disease and its risk factors including high blood pressure and dyslipidaemia. Black tea is fully fermented and during this process polyphenols are oxidised into pigments and may lose their antioxidant effects. Second, black tea is often served with milk, which previous research has shown may counteract the favourable health effects of tea on vascular function. Gender-specific analyses showed that the protective effects of habitual tea consumption were pronounced and robust across different outcomes for men, but only modest for women. Dr. Wang said: "One reason might be that 48% of men were habitual tea consumers compared to just 20% of women. Secondly, women had much lower incidence of, and mortality from, heart disease and stroke. These differences made it more likely to find statistically significant results among men." She added: "The China-PAR project is ongoing, and with more person-years of follow-up among women the associations may become more pronounced." The authors concluded that randomized trials are warranted to confirm the findings and provide evidence for dietary guidelines and lifestyle recommendations. Funding: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2017-I2M-1-004); National Key R&D Program of China (2017YFC0211700 and 2018YFC1311703).
  • Contacts and sources: The European Society of Cardiology
  • Publication: Tea consumption and the risk of atherosclerotic cardiovascular disease and all-cause mortality: The China-PAR project. Wang X, Liu F, Li J, et al. . Eur J Prev Cardiol. 2019. doi:10.1177/2047487319894685.
  • 2China-PAR: Prediction for ASCVD Risk in China project Source: https://www.ineffableisland.com:
Read More........

India's first vaccine candidate Covaxin's Phase-3 trials begin


Vaccine maker Bharat Biotech has announced that it has commenced Phase-3 trials of Covaxin, India's first indigenous vaccine for COVID-19.

The Phase-3 trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR).

This is India's first Phase-3 efficacy study for a COVID-19 vaccine, and the largest Phase-3 efficacy trial ever conducted in India, the Hyderabad-based company said.

Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to receive Covaxin or a placebo. The trial is double blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group.

The trials are being conducted at 22 institutes in India including the All India Institute of Medical Sciences (AIIMS), the Guru Tegh Bahadur Hospital (both New Delhi), the Aligarh Muslim University, the Grant Government Medical College and Sir J.J. Group of Hospitals, Lokmanya Tilak Municipal General Hospital and Medical College (Sion Hospital) (all three Mumbai), the ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, the Directorate of Public Health and Preventive Medicine, Chennai and King George Hospital, Vizag.

Participating volunteers, who undergo vaccination in the Phase-3 trials, will be monitored to detect occurrence of COVID-19.

Covaxin has been evaluated in about 1,000 subjects in Phase-1 and Phase-2 clinical trials, with promising safety and immunogenicity data. Volunteers who wish to participate in this trial should be adults over 18 years of age.

Covaxin by Bharat Biotech is developed in collaboration with the ICMR - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio containment facility.

Covaxin is a highly purified and inactivated vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.

"The development and clinical evaluation of Covaxin marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. Covaxin has garnered interest from several countries worldwide for supplies and introduction," said Suchitra Ella, Joint Managing Director of Bharat Biotech Source: https://southasiamonitor.org/
Read More........